Christina Huddleston, MD
Allergy · Dallas, TXNPI 1598110462
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,450 of the $25,559 with a category attached, or 68.3%. AstraZeneca accounts for 76.0% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $20,574, more than ten times the $723 reported in 2019. Among allergy clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 327 payments — averaging $78.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$19K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$915
- Takeda Pharmaceuticals U.S.A., Inc.$645
- GSK$623
- Genentech USA, Inc.$322
- plus $2K from 29 others
What the payments were for
- Consulting fees$510%
- Speaking & faculty fees$17,45068%
- Grants$7003%
- Travel & lodging$6863%
- Food & beverage$6,36325%
- Education$3101%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 74 | $19,418 |
| Sanofi | 20 | $1,231 |
| Regeneron Healthcare Solutions, Inc. | 44 | $915 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $645 |
| GSK | 41 | $623 |
| Genentech USA, Inc. | 11 | $322 |
| Grifols USA, LLC | 15 | $265 |
| Novartis | 14 | $255 |
| Amgen | 10 | $207 |
| Sanofi-aventis U.S. LLC | 2 | $199 |
| Biocryst US Sales Co., LLC | 10 | $194 |
| CSL Behring | 7 | $175 |
| LEO Pharma Inc. | 6 | $147 |
| Octapharma USA, Inc. | 5 | $117 |
| Optinose US, Inc. | 6 | $115 |
| Azurity Pharmaceuticals, Inc. | 4 | $67 |
| Pfizer | 3 | $65 |
| Teva Pharmaceuticals USA, Inc. | 2 | $61 |
| Covis Pharma GmbH | 3 | $57 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $56 |
| Blueprint Medicines Corporation | 3 | $56 |
| AbbVie | 2 | $54 |
| ADMA Biomanufacturing LLC | 2 | $51 |
| Organon | 4 | $37 |
| Lilly USA, LLC | 1 | $26 |
| Greer Laboratories, Inc. | 1 | $26 |
| Arcutis Biotherapeutics, Inc. | 1 | $23 |
| Pharming Healthcare, Inc. | 1 | $23 |
| Insmed, Inc. | 1 | $22 |
| Kaleo, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $20 |
| Hospira, Inc. | 1 | $19 |
| GC Biopharma USA, Inc. | 1 | $18 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,559 in reported general payments places this provider in the 95th percentile of 69 allergy providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 11 | $40,262 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $25,700 |
| XolairOmalizumab | 14 | $19,389 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $5,375 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $4,210 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $1,918 |
| Ipratropium Bromide | 34 | $1,027 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $592 |
| Azelastine Hcl | 24 | $572 |
| Montelukast Sodium | 88 | $375 |
| Fluticasone Propionate | 22 | $233 |
| Prednisone | 18 | $29 |
| Azithromycin | 15 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $623 | $25,70035 claims |
| AstraZenecaSymbicort | $19,418 | $4,21017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 69 allergy providers in Texas.
Other allergy in Dallas
- Gary GrossDallas$602K
- Sandeep GuptaDallas$10K
- Erin ClarkeDallas$8K
- Michael RuffDallas$5K
- Steven ColeDallas$5K
- Tran LyDallas$4K
- Rene LeonSouthlake$48K
- Alireza ShakouriSouthlake$17K
- Zachary MarshallRoanoke$17K
- Stuart AbramsonSan Angelo$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.